All In Biotech

Drug Trial Radar · NCT05871970

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

38

Planned (sponsor's estimate)

Start

Oct 18, 2023

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Protara TherapeuticsIndustry
Sponsor type
Industry
First posted
May 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6 months to less than 2 years. The Phase 2b is an expansion study in which enrollment of participants will be initiated after safety has been established in each cohort during the Phase 2a safety lead-in study. Each participant will receive up to 4 injections of TARA-002 spaced approximately 6 weeks apart.

Conditions

  • Lymphatic Malformation

Interventions

  • TARA-002Biological

    All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with clinical success after one treatment cycle of TARA-002Time frame: 8 weeks after the last injection

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama · Recruiting

  • Arkansas Children's Hospital/UAMS

    Little Rock, Arkansas · Recruiting

  • Children's Hospital of Colorado

    Aurora, Colorado · Recruiting

  • Children's National Medical Center: Children's Research Institute

    Washington D.C., District of Columbia · Recruiting

  • Nemours Children's Clinic - Jacksonville

    Jacksonville, Florida · Recruiting

  • Mount Sinai Hospital

    New York, New York · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Withdrawn

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Children's Hospital of Philadelphia: Comprehensive Vascular Anomalies Program

    Philadelphia, Pennsylvania · Withdrawn

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Children's Hospital of the King's Daughters

    Norfolk, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.